NYSE$ABT
Abbott Laboratories · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Second quarter results were announced, with sales driven by strong underlying base business performance and an increased outlook for the underlying base business.
Abbott's second-quarter 2023 results revealed a decrease in reported sales by 11.4 percent, attributed to an anticipated decline in COVID-19 testing-related sales. However, the underlying base business demonstrated strength, with organic sales growth of 11.5 percent, led by Medical Devices, Established Pharmaceuticals, and Nutrition. The company is strengthening its portfolio through new product approvals and expanded reimbursement coverage.
- GAAP diluted EPS was $0.78, and adjusted diluted EPS was $1.08, excluding specified items.
- Full-year 2023 diluted EPS is projected to be $3.02 to $3.22 on a GAAP basis.
- The adjusted EPS for the full year is projected to be $4.30 to $4.50, reflecting an increased outlook for the underlying base business offset by lower forecasted earnings from COVID-19 testing-related sales.
- Full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, is projected to be in the low double-digits, with COVID-19 testing-related sales of approximately $1.3 billion.
Headline financials
Revenue & EPS history
Abbott · Revenue · Quarterly
$9.98B
Revenue by segment
Abbott · $6.61B total across 2 segments · Q2 2023
- Medical Devices$4.3B—65.0%
- Diagnostics$2.32B—35.0%
Forward guidance
Abbott projects full-year 2023 diluted earnings per share under GAAP of $3.02 to $3.22. Excluding specified items, projected adjusted diluted earnings per share would be $4.30 to $4.50 for the full-year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.6%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.1%
Avg return
30 days after
61%
45 / 74 earnings
Positive
+10.3%
Q3 2013
Best reaction
-9.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -8.7% | -16.8% | |
| Q4 2025 | -9.9% | -10.3% | -7.1% | |
| Q3 2025 | -2.9% | -2.8% | -2.0% | |
| Q2 2025 | -0.1% | +1.4% | +3.3% | |
| Q1 2025 | +2.8% | +2.9% | +6.8% | |
| Q4 2024 | +0.8% | +10.8% | +15.5% | |
| Q3 2024 | +1.6% | +0.8% | -0.1% | |
| Q2 2024 | -2.5% | -0.7% | +6.0% | |
| Q1 2024 | -3.6% | -2.0% | -4.7% | |
| Q4 2023 | -1.4% | -0.5% | +4.8% | |
| Q3 2023 | +3.6% | +4.0% | +8.0% | |
| Q2 2023 | +6.5% | +5.3% | -3.3% | |
| Q1 2023 | +6.0% | +6.0% | +4.6% | |
| Q4 2022 | -1.3% | -2.4% | -10.7% | |
| Q3 2022 | -9.3% | -6.4% | -1.1% | |
| Q2 2022 | +0.7% | -1.3% | +0.1% | |
| Q1 2022 | +2.8% | +0.0% | -5.6% | |
| Q4 2021 | -2.3% | +3.4% | -0.7% | |
| Q3 2021 | +4.8% | +6.1% | +6.3% | |
| Q2 2021 | +1.5% | +0.7% | +6.2% | |
| Q1 2021 | -1.5% | -1.0% | -5.4% | |
| Q4 2020 | +4.9% | +6.8% | +4.4% | |
| Q3 2020 | +1.0% | +0.6% | +2.3% | |
| Q2 2020 | +2.6% | +1.5% | +3.4% | |
| Q1 2020 | +5.6% | +3.4% | -1.2% | |
| Q4 2019 | +1.1% | -0.2% | -2.5% | |
| Q3 2019 | +0.5% | -0.4% | +4.5% | |
| Q2 2019 | +5.5% | +5.9% | +1.9% | |
| Q1 2019 | -3.2% | -2.4% | -0.5% | |
| Q4 2018 | -0.9% | -3.4% | +6.5% | |
| Q3 2018 | -4.0% | -3.4% | +1.5% | |
| Q2 2018 | +1.6% | +0.6% | +3.1% | |
| Q1 2018 | +0.1% | -1.6% | +3.2% | |
| Q4 2017 | +6.7% | +6.9% | +0.8% | |
| Q3 2017 | +1.7% | +1.9% | +0.9% | |
| Q2 2017 | +2.9% | +2.8% | -1.4% | |
| Q1 2017 | +1.3% | +1.6% | -0.6% | |
| Q4 2016 | +1.6% | +1.6% | +12.5% | |
| Q3 2016 | -1.0% | -1.8% | -3.2% | |
| Q2 2016 | +3.0% | +3.9% | +5.8% | |
| Q1 2016 | +0.1% | — | — | |
| Q4 2015 | -6.5% | — | — | |
| Q3 2015 | +4.2% | — | — | |
| Q2 2015 | +2.9% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +3.1% | — | — | |
| Q3 2014 | +0.1% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | +2.5% | — | — | |
| Q4 2013 | -4.3% | — | — | |
| Q3 2013 | +10.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -7.6% | — | — | |
| Q2 2012 | -1.0% | — | — | |
| Q1 2012 | -1.5% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2011 | -0.4% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q1 2008 | +1.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -0.8% | — | — | |
| Q2 2010 | +0.7% | — | — | |
| Q1 2009 | -1.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | -1.1% | — | — | |
| Q4 2009 | -1.1% | — | — | |
| Q3 2008 | +1.4% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q2 2009 | +2.1% | — | — | |
| Q4 2008 | +2.1% | — | — | |
| Q2 2008 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro